Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y. Ho, Eugene Braunwald, Sharlene M. Day et al.|Nature Medicine|2021Cited by 132
Prediction of Sarcomere Mutations in Subclinical Hypertrophic CardiomyopathyGabriella Captur, James Moon, Luís R. Lopes et al.|Circulation Cardiovascular Imaging|2014Cited by 111
Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac DiseaseMichael A. Portman, Valerii Digtiar, Kristin Shimano et al.|Journal of the American College of Cardiology|2022Cited by 59
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G. Ireland, Carolyn Y. Ho, Danielle S. Burstein et al.|Circulation Heart Failure|2024Cited by 6
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin‐Cristian Topriceanu, Carolyn Y. Ho, Christoffer Rasmus Vissing et al.|Circulation Heart Failure|2025Cited by 3